Literature DB >> 24596716

Phenotypic and Genetic Characterization of Carbapenemase and ESBLs Producing Gram-negative Bacteria (GNB) Isolated from Patients with Cystic Fibrosis (CF) in Tehran Hospitals.

Parisa Vali1, Fereshteh Shahcheraghi2, Maryam Seyfipour3, Maryam Alsadat Zamani3, Mohammad Reza Allahyar3, Mohammad Mehdi Feizabadi4.   

Abstract

BACKGROUND: Cystic Fibrosis (CF) is an autosomal recessive genetic disorder in white populations caused by mutation in a gene that encodes Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. Since frequent respiratory tract infections are the major problem in patients with CF, obligation to identify the causative bacteria and determining their antibiotic resistance pattern is crucial. The purpose of this project was to detect Gram-negative bacteria (GNB) isolated from sputa of CF patients and to determine their antibiotic resistance pattern.
MATERIALS AND METHODS: The sputum of 52 CF patients, treated as inpatients at hospitals in Tehran, was obtained between November 2011 and June 2012. Samples cultured in selective and non-selective media and GNB recognized by biochemical tests. Antimicrobial susceptibility testing to cephalosporins, aminoglycosides and carbapenems was performed by disk diffusion method and MICs of them were measured. For phenotypic detection of carbapenemase and ESBLs production, the Modified Hodge test, double disk synergy test and the combined disk methods were performed. Subsequently, the genes encoding the extended spectrum beta-lactamases (blaPER, blaCTX-M) and carbapenemases (blaIMP-1, blaGES, blaKPC, blaNDM, blaVIM-1, blaVIM-2, blaSPM, blaSIM) in Gram negative bacteria were targeted among the resistant isolates by using PCR. PFGE was used to determine any genetic relationship among the Pseudomonas aeruginosa isolated from these patients.
RESULTS: Fifty five GNB were isolated from 52 sputum samples including Pseudomonas aeruginosa, Klebsiella ozaenae, Alcaligenes xylosoxidans, Achromobacter denitrificans, Klebsiella pneumonia and Stenotrophomonas maltophilia. The rates of resistance to different antibiotic were as follows: cefixime (%80), ceftriaxone (%43), ceftazidime (%45) and meropenem (%7). The prevalence of genes encoding the ESBLs and Carbapenemases among the the phenotypically positive strains were as follows: blaCTX-M (19), blaIMP-1 (2), blaVIM-1 (2) and blaVIM-2 (3) genes respectively. No other genes were detected. PFGE analysis revealed 8 genotypes. Six isolates had mutually 3 similar patterns.
CONCLUSION: This study showed the existence of important ESBLs and carbapenemases genes among the GNB isolated from patients with CF. Continuous surveillance of ESBLs and Carbapenemases, also identification of their types, in bacteria isolated from these patients have an important clinical impact, since, it can often provide valuable information for effective infection control measures and for the choice of appropriate antimicrobial therapy.

Entities:  

Keywords:  Carbapenemase; Cystic fibrosis; Gram-negative Bacteria (GNB); Polymerase Chain Reaction

Year:  2014        PMID: 24596716      PMCID: PMC3939568          DOI: 10.7860/JCDR/2014/6877.3916

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  41 in total

1.  Multidrug-resistant Pseudomonas aeruginosa isolate co-expressing extended-spectrum beta-lactamase PER-1 and metallo-beta-lactamase VIM-2 from Turkey.

Authors:  Yusuf Yakupogullari; Laurent Poirel; Sandrine Bernabeu; Ahmet Kizirgil; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2007-11-02       Impact factor: 5.790

2.  Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea.

Authors:  Kyungwon Lee; Jong Hwa Yum; Dongeun Yong; Hyuk Min Lee; Heung Dong Kim; Jean-Denis Docquier; Gian Maria Rossolini; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 3.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Prevalence and antimicrobial susceptibility of respiratory pathogens in patients with cystic fibrosis.

Authors:  Vilma Almeida Paixão; Tânia Fraga Barros; Clélia Maria C Mota; Tamy Fagundes Moreira; Maria Angélica Santana; Joice Neves Reis
Journal:  Braz J Infect Dis       Date:  2010 Jul-Aug       Impact factor: 1.949

5.  Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.

Authors:  L Poirel; T Naas; D Nicolas; L Collet; S Bellais; J D Cavallo; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Chloride impermeability in cystic fibrosis.

Authors:  P M Quinton
Journal:  Nature       Date:  1983-02-03       Impact factor: 49.962

7.  Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.

Authors:  E Osano; Y Arakawa; R Wacharotayankun; M Ohta; T Horii; H Ito; F Yoshimura; N Kato
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

8.  Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens.

Authors:  H Ito; Y Arakawa; S Ohsuka; R Wacharotayankun; N Kato; M Ohta
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

9.  Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.

Authors:  Fred C Tenover; Rajinder K Kalsi; Portia P Williams; Roberta B Carey; Sheila Stocker; David Lonsway; J Kamile Rasheed; James W Biddle; John E McGowan; Bruce Hanna
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

10.  Emergence of New Delhi metallo-β-lactamase, Austria.

Authors:  Gernot Zarfel; Martin Hoenigl; Eva Leitner; Helmut J F Salzer; Gebhard Feierl; Lilian Masoud; Thomas Valentin; Robert Krause; Andrea J Grisold
Journal:  Emerg Infect Dis       Date:  2011-01       Impact factor: 6.883

View more
  8 in total

Review 1.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

2.  Identification and characterization of bacteria isolated from patients with cystic fibrosis in Jordan.

Authors:  Nid'a Alshraiedeh; Farah Atawneh; Rasha Bani-Salameh; Rawan Alsharedeh; Yara Al Tall; Mohammad Alsaggar
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 3.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 4.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

Review 5.  The threat of carbapenem-resistant gram-negative bacteria in a Middle East region.

Authors:  Effat Davoudi-Monfared; Hossein Khalili
Journal:  Infect Drug Resist       Date:  2018-10-17       Impact factor: 4.003

6.  EXTENDED-SPECTRUM BETA-LACTAMASE PRODUCING GRAM NEGATIVE BACTERIA IN IRAN: A REVIEW.

Authors:  Hamed Ebrahimzadeh Leylabadlo; Tala Pourlak; Abed Zahedi Bialvaei; Mohammad Aghazadeh; Mohammad Asgharzadeh; Hossein Samadi Kafil
Journal:  Afr J Infect Dis       Date:  2017-06-08

7.  Clinical Outcomes Associated With Escherichia coli Infections in Adults With Cystic Fibrosis: A Cohort Study.

Authors:  B D Edwards; R Somayaji; J Greysson-Wong; C Izydorczyk; B Waddell; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  Open Forum Infect Dis       Date:  2019-11-18       Impact factor: 3.835

8.  An 18-Year Dataset on the Clinical Incidence and MICs to Antibiotics of Achromobacter spp. (Labeled Biochemically or by MAL-DI-TOF MS as A. xylosoxidans), Largely in Patient Groups Other than Those with CF.

Authors:  Claudio Neidhöfer; Christina Berens; Marijo Parčina
Journal:  Antibiotics (Basel)       Date:  2022-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.